CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that researchers have completed preliminary preclinical studies showing that ranolazine increased glucose stimulated insulin secretion in pancreatic beta cells. In separate experiments using preclinical models of insulin resistance, ranolazine also improved glucose homeostasis. [click link for full article]
More...